Drugs / GSK2646264
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02927457 | Jan 2017 → Jun 2018 | cutaneous lupus erythematosus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT02424799 | Nov 2014 → Nov 2017 | urticaria | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK2646264 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02424799 ↗ |
| Action | Inhibit | “the selective SYK inhibitor GSK2646264 in active CLE lesions” PMID 33336508 ↗ Dec 2020 |
| Route | Topical | “after single and repeat topical applications of up to 2 strengths of GSK2646264” NCT02424799 ↗ |
| Target | SYK | “the selective SYK inhibitor GSK2646264 in active CLE lesions” PMID 33336508 ↗ Dec 2020 |